- Filed
- Oct 5, 2026
- Last modified
- Oct 5, 2026
- Petitioner
- BMJ Publishing Group Limited
- Inventor
- Carl BATE et al
Invalidity dossier
US 12518882
Added 10/6/2026, 12:00:18 AM
Active provider: DeepSeek · deepseek-v4-flash
Patent summary
Title, assignee, inventors, filing/issue dates, abstract, and a plain-language overview of the claims.
Patent Overview — US 12518882 B2
Title: Translation of medical evidence into computational evidence and applications thereof
Assignee: Evidium Inc (original and current; assignment recorded 2025-02-25)
Key dates (as listed): Priority date 2022-04-15; application filed 2025-02-04 (application number US19/045,329); publication US20250182911A1 on 2025-06-05; patent granted and published 2026-01-06; anticipated expiration 2043-04-14. Legal status listed as Active. Inventors listed include Carl Bate, Wian Stipp, Thomas Unger, David A. Epstein, Matthew McSorley, Fady Nakhla, David Robinson, Jennifer May Lee, and Arthur Böök.
Purpose: Medical evidence is described as predominantly narrative and document-based, producing problems such as delay from bench to bedside, ineffective manual search, alert fatigue from hard-coded rules, and sparse feedback from practice to research. The patent addresses this by making medical evidence computational and queryable by any application.
Plain-language scope: A "computational evidence platform" extracts medical evidence or clinical guidelines from any source and places it into a structured computational representation. A database of interlinked computational elements—conditions, diagnostic factors, risk factors, and investigations—lets applications query the evidence and map it to external data such as a patient chart. Embodiments cover: (1) representing clinical concepts as elemental factors and investigations that are shareable across conditions and linked in a database; (2) determining a patient's clinical state from those elements; and (3) determining next-best actions for that patient. The described process may combine ontologies and evidence sources (e.g., SNOMED-CT, LOINC, RxNORM). Stanson Health, rules engines, and SNOMED-CT reasoning limits are discussed as background, not as asserted prior art.
Source: https://patents.google.com/patent/US12518882/en
What the excerpt does not establish: It does not establish the full claim scope, prosecution history, validity, ownership history beyond the recorded assignment, or litigation. The excerpt is partial, and it states that priority dates, legal status, and assignee listings are assumptions, not legal conclusions.
Generated 10/6/2026, 12:00:48 AM
Cases on file (0)
Specific litigation cases in our database that name US patent 12518882. The free-form analysis below may also discuss cases beyond this list.
No cases on file mention this patent. Upload a CSV or add a case manually in Admin → Manage litigation cases.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Proceedings on file (1)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Assignment history
Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.
Prior art
Earlier patents, publications, and products that may anticipate or render the claims unpatentable.
Obviousness
Combinations of prior art that suggest the claimed invention would have been obvious under 35 U.S.C. § 103.
Extensions
Patent term adjustments, term extensions, continuations, divisionals, family members, and expiration dates.
Derivative works
Defensive disclosure: derivative variations of each claim designed to render future incremental improvements obvious or non-novel.